Challenges in Steroid and Anticoagulant Therapy in Severe COVID-19 Pneumonia: A Prospective Study.

Alaa Thabet HassanAlaa E Abd Elmoniem Marwa Mahmoud AbdelradyMona Embarek MohamedMohamed Ahmed El-MokhtarAbdelhalim A ElsherifGhada Mohamed SaiedSoheir M Kasem

Published in: Antibiotics (Basel, Switzerland) (2021)

the use of combined methylprednisolone and therapeutic Enoxaparin, according to a flexible protocol for COVID-19 patients with severe pneumonia, had two benefits; the prevention of disease complications and improved clinical outcome.

Keyphrases

coronavirus disease
sars cov
venous thromboembolism
early onset
randomized controlled trial
atrial fibrillation
high dose
respiratory syndrome coronavirus
respiratory failure
risk factors
community acquired pneumonia
low dose
mesenchymal stem cells